Stem Cell Therapies: Upcoming Opportunities in Cardiovascular and Metabolic Disorders (CVMD)

Cardiovascular disorders and metabolic disorders are considered to be amongst the leading causes of death worldwide. In fact, approximately one-third of the annual number of deaths across the globe are attributed to cardiovascular disorders.  Likewise, a significant proportion of the global population suffers from diabetes or some form of metabolism related clinical condition. As per IDF Diabetes Atlas, the treatment of diabetes and related complications incurred USD 727 billion in global healthcare expenditure in 2017. Advances in cell biology and regenerative medicine have led to the development of stem cell therapies that can potentially address several unmet needs and potentially offer a cure for various cardiovascular and metabolic disorders.

I have highlighted below some of the most interesting insights from our study. You can also access additional details here.

The present treatment landscape of cardiovascular and metabolic diseases is characterized by a variety of unmet needs; stem cell therapies have emerged as a viable therapeutic option

Opinions of industry experts and patients, expressed across numerous scientific articles and online portals, highlight the existence of several unmet needs related to the treatment of cardiovascular & metabolic disorders

Presently, over 60 stem cell therapies are being evaluated across different phases of development for a variety of cardiovascular diseases and chronic metabolism-related disorders

The current pipeline features a mix of autologous and allogeneic therapies; diverse routes of administration are presently being explored for the administration of such therapies

In order to achieve a competitive edge, therapy developers are increasingly focusing on conducting clinical trials across different geographies for multiple indications

Investors have realized the potential of stem cell-based therapies in treating these disorders; over USD 2 billion has recently been raised across more than 120 funding instances

In addition, there has been a surge in partnership activity, especially R&D related deals; innovation is being driven by both industry / academic players and is evident across peer reviewed scientific literature

As multiple late stage molecules get commercialized in near future, the market for stem cell therapies for cardiovascular & metabolic disorders is poised to grow significantly

The overall opportunity is well distributed across the various types of stem cells used, routes of administration and geographical regions

To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at

You may also be interested in the following titles:

  1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
  2. Fc Protein and Glyco-engineered Antibodies Market: Focus on Type of Fc Engineering and Therapeutics (3rd edition), 2021-2030
  3. Bronchial Spasm: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

Our Social Media Platform